Pulmonary Arterial Hypertension (PAH) Market Report

Global and Region Pulmonary Arterial Hypertension (PAH) Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：210
  • REPORT CODE：GMM1007867
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Pulmonary hypertension is a condition of increased blood pressure within the arteries of the lungs.[6] Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat.

    The report details the trend, potential and market size of Pulmonary Arterial Hypertension (PAH) market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Pulmonary Arterial Hypertension (PAH)market, defines the market attractiveness level of Pulmonary Arterial Hypertension (PAH) market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Pulmonary Arterial Hypertension (PAH) industry, describes the types of Pulmonary Arterial Hypertension (PAH) market, the applications of major players and the market size, and deeply analyzes the current situation of the global Pulmonary Arterial Hypertension (PAH) market and the development prospects and opportunities of Pulmonary Arterial Hypertension (PAH) industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) market in Chapter 13.

    By Player:

    • Pfizer

    • Bayer

    • United Therapeutics

    • Gilead Sciences

    • Arena

    • GlaxoSmithKline

    • Actelion

    By Type:

    • Prostacyclin and Prostacyclin Analogs

    • SGC Stimulators

    • ERA

    • PDE-5

    By End-User:

    • Hospital

    • Clinic

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Pulmonary Arterial Hypertension (PAH) Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Pulmonary Arterial Hypertension (PAH) Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Pulmonary Arterial Hypertension (PAH) Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Pulmonary Arterial Hypertension (PAH) Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Market Analysis and Outlook to 2022

    • 7.1 Global Pulmonary Arterial Hypertension (PAH) Consumption (2017-2022)

    • 7.2 United States Pulmonary Arterial Hypertension (PAH) Consumption (2017-2022)

    • 7.3 Europe Pulmonary Arterial Hypertension (PAH) Consumption (2017-2022)

    • 7.4 China Pulmonary Arterial Hypertension (PAH) Consumption (2017-2022)

    • 7.5 Japan Pulmonary Arterial Hypertension (PAH) Consumption (2017-2022)

    • 7.6 India Pulmonary Arterial Hypertension (PAH) Consumption (2017-2022)

    • 7.7 South Korea Pulmonary Arterial Hypertension (PAH) Consumption (2017-2022)

    8 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Market Analysis and Outlook to 2028

    • 8.1 Global Pulmonary Arterial Hypertension (PAH) Consumption Forecast (2022-2028)

    • 8.2 United States Pulmonary Arterial Hypertension (PAH) Consumption Forecast (2022-2028)

    • 8.3 Europe Pulmonary Arterial Hypertension (PAH) Consumption Forecast (2022-2028)

    • 8.4 China Pulmonary Arterial Hypertension (PAH) Consumption Forecast (2022-2028)

    • 8.5 Japan Pulmonary Arterial Hypertension (PAH) Consumption Forecast (2022-2028)

    • 8.6 India Pulmonary Arterial Hypertension (PAH) Consumption Forecast (2022-2028)

    • 8.7 South Korea Pulmonary Arterial Hypertension (PAH) Consumption Forecast (2022-2028)

    9 Global Pulmonary Arterial Hypertension (PAH) Market Outlook by Types and Applications to 2022

    • 9.1 Global Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Prostacyclin and Prostacyclin Analogs Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global SGC Stimulators Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global ERA Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global PDE-5 Consumption and Growth Rate (2017-2022)

    • 9.2 Global Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

    10 Global Pulmonary Arterial Hypertension (PAH) Market Outlook by Types and Applications to 2028

    • 10.1 Global Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Prostacyclin and Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global SGC Stimulators Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global ERA Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global PDE-5 Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    11 Global Pulmonary Arterial Hypertension (PAH) Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Pulmonary Arterial Hypertension (PAH) Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Pulmonary Arterial Hypertension (PAH) Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Pulmonary Arterial Hypertension (PAH) Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Pulmonary Arterial Hypertension (PAH) Market Competitive Analysis

    • 14.1 Pfizer

      • 14.1.1 Pfizer Company Details

      • 14.1.2 Pfizer Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Product and Service

    • 14.2 Bayer

      • 14.2.1 Bayer Company Details

      • 14.2.2 Bayer Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Bayer Pulmonary Arterial Hypertension (PAH) Product and Service

    • 14.3 United Therapeutics

      • 14.3.1 United Therapeutics Company Details

      • 14.3.2 United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Product and Service

    • 14.4 Gilead Sciences

      • 14.4.1 Gilead Sciences Company Details

      • 14.4.2 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product and Service

    • 14.5 Arena

      • 14.5.1 Arena Company Details

      • 14.5.2 Arena Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Arena Pulmonary Arterial Hypertension (PAH) Product and Service

    • 14.6 GlaxoSmithKline

      • 14.6.1 GlaxoSmithKline Company Details

      • 14.6.2 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product and Service

    • 14.7 Actelion

      • 14.7.1 Actelion Company Details

      • 14.7.2 Actelion Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Actelion Pulmonary Arterial Hypertension (PAH) Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Pulmonary Arterial Hypertension (PAH)

    • Figure Pulmonary Arterial Hypertension (PAH) Picture

    • Table Global Pulmonary Arterial Hypertension (PAH) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Pulmonary Arterial Hypertension (PAH) Consumption by Country (2017-2022)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate (2017-2022)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate (2017-2022)

    • Figure China Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate (2017-2022)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate (2017-2022)

    • Figure India Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Consumption and Growth Rate (2017-2022)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Consumption Forecast by Country (2022-2028)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prostacyclin and Prostacyclin Analogs Consumption and Growth Rate (2017-2022)

    • Figure Global SGC Stimulators Consumption and Growth Rate (2017-2022)

    • Figure Global ERA Consumption and Growth Rate (2017-2022)

    • Figure Global PDE-5 Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Prostacyclin and Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global SGC Stimulators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ERA Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PDE-5 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Pulmonary Arterial Hypertension (PAH) Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Pulmonary Arterial Hypertension (PAH) Export by Region (Top 5 Countries) (2017-2028)

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Pulmonary Arterial Hypertension (PAH) Product and Service

    • Table United Therapeutics (Foundation Year, Company Profile and etc.)

    • Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

    • Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Product and Service

    • Table Gilead Sciences (Foundation Year, Company Profile and etc.)

    • Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product and Service

    • Table Arena (Foundation Year, Company Profile and etc.)

    • Table Arena Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arena Pulmonary Arterial Hypertension (PAH) Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product and Service

    • Table Actelion (Foundation Year, Company Profile and etc.)

    • Table Actelion Pulmonary Arterial Hypertension (PAH) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Actelion Pulmonary Arterial Hypertension (PAH) Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US